𝔖 Bobbio Scriptorium
✦   LIBER   ✦

High-dose medroxyprogesterone acetate in advanced ovarian cancer

✍ Scribed by M. A. QUINN; R. M. ROME; P. GRANT; R. S. PLANNER


Book ID
109085230
Publisher
John Wiley and Sons
Year
1991
Tongue
English
Weight
202 KB
Volume
1
Category
Article
ISSN
1048-891X

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Medroxyprogesterone acetate bioavailabil
✍ Carlo M. Camaggi; Elena Strocchi; Barbara Costanti; Paola Beghelli; Patrizio Fer πŸ“‚ Article πŸ“… 1985 πŸ› Springer 🌐 English βš– 273 KB

Administration of medroxyprogesterone acetate IP in advanced cancer with peritoneal metastases and ascitic effusion generates considerably higher drug plasma levels than those observed after PO or IM treatment. Comparison of areas under the time-concentration curves (AUC) with reference to the three

A phase II study of high-dose medroxypro
✍ Geoffrey Falkson; HΓ¨ndrΓ© C. Falkson πŸ“‚ Article πŸ“… 1983 πŸ› Springer 🌐 English βš– 215 KB

Twenty-three evaluable patients with advanced breast cancer were treated with MPA, 1,400 mg/m2 daily PO for the first 6 months, and 500 mg/m2 daily PO thereafter. The median total dose was 191,400 mg in 88 days, with the maximum dose given to date 522,600 mg in 282 days. Most patients tolerated high

Medroxyprogesterone acetate (MAP) plasma
✍ Carlo Maurizio Camaggi; Elena Strocchi; Michele Giovannini; Bruna Angelelli; Bar πŸ“‚ Article πŸ“… 1983 πŸ› Springer 🌐 English βš– 352 KB

Medroxyprogesterone acetate plasma levels were measured in advanced cancer patients after multiple PO or IM administration (500, 1000, 2000, 3000, 4000, and 5000 mg/day PO and 500, 1000, 2000 mg/day IM for 30 days). After PO administration, the plasma concentration rises quickly and plateau level is